NCT01612468View on ClinicalTrials.gov

Liraglutide in Type 1 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Diabetes Mellitus, Type 1Overweight
Interventions
DRUG

Liraglutide

1.8 mg/day subcutaneous

DRUG

Placebo

1.8 mg/day subcutaneous

Trial Locations (1)

2820

Steno Diabetes Center, Gentofte Municipality

All Listed Sponsors
collaborator

University Hospital, Gentofte, Copenhagen

OTHER

collaborator

University of Copenhagen

OTHER

lead

Steno Diabetes Center Copenhagen

OTHER

NCT01612468 - Liraglutide in Type 1 Diabetes | Biotech Hunter | Biotech Hunter